Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma.

Goswami RS, Atenafu EG, Xuan Y, Waldron L, Reis PP, Sun T, Datti A, Xu W, Kuruvilla J, Good DJ, Lai R, Church AJ, Lam WS, Baetz T, Lebrun DP, Sehn LH, Farinha P, Jurisica I, Bailey DJ, Gascoyne RD, Crump M, Kamel-Reid S.

J Clin Oncol. 2013 Aug 10;31(23):2903-11. doi: 10.1200/JCO.2012.45.3050.

PMID:
23835716
2.

Methylation of miR-155-3p in mantle cell lymphoma and other non-Hodgkin's lymphomas.

Yim RL, Wong KY, Kwong YL, Loong F, Leung CY, Chu R, Lam WW, Hui PK, Lai R, Chim CS.

Oncotarget. 2014 Oct 30;5(20):9770-82.

3.

microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma.

Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W, Dessureault S, Moscinski LC, Rezania D, Dalton WS, Sotomayor E, Tao J, Cheng JQ.

Blood. 2010 Apr 1;115(13):2630-9. doi: 10.1182/blood-2009-09-243147.

4.

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.

Husby S, Ralfkiaer U, Garde C, Zandi R, Ek S, Kolstad A, Jerkeman M, Laurell A, Räty R, Pedersen LB, Pedersen A, Ehinger M, Sundström C, Karjalainen-Lindsberg ML, Delabie J, Clasen-Linde E, Brown P, Cowland JB, Workman CT, Geisler CH, Grønbæk K.

Blood. 2015 Apr 23;125(17):2669-77. doi: 10.1182/blood-2014-06-584193.

5.

Mantle cell lymphoma: transcriptional regulation by microRNAs.

Di Lisio L, Gómez-López G, Sánchez-Beato M, Gómez-Abad C, Rodríguez ME, Villuendas R, Ferreira BI, Carro A, Rico D, Mollejo M, Martínez MA, Menárguez J, Díaz-Alderete A, Gil J, Cigudosa JC, Pisano DG, Piris MA, Martínez N.

Leukemia. 2010 Jul;24(7):1335-42. doi: 10.1038/leu.2010.91.

PMID:
20485376
6.

MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in Mantle cell lymphomas.

Navarro A, Beà S, Fernández V, Prieto M, Salaverria I, Jares P, Hartmann E, Mozos A, López-Guillermo A, Villamor N, Colomer D, Puig X, Ott G, Solé F, Serrano S, Rosenwald A, Campo E, Hernández L.

Cancer Res. 2009 Sep 1;69(17):7071-8. doi: 10.1158/0008-5472.CAN-09-1095.

7.

[Expression of SOX11 mRNA in mantle cell lymphoma and its clinical significance].

Wang YY, Yu Z, Yi SH, Li ZJ, Li CH, Xie ZQ, Li F, Zang MR, Hao M, Qiu LG.

Zhonghua Xue Ye Xue Za Zhi. 2012 Jul;33(7):556-60. Chinese.

PMID:
22967417
8.

microRNA levels in paraffin-embedded indolent B-cell non-Hodgkin lymphoma tissues from patients chronically infected with hepatitis B or C virus.

Bruni R, Marcantonio C, Pulsoni A, Tataseo P, De Angelis F, Spada E, Marcucci F, Panfilio S, Bianco P, Riminucci M, Villano U, Tosti M, Ciccaglione A, Mele A.

BMC Infect Dis. 2014;14 Suppl 5:S6. doi: 10.1186/1471-2334-14-S5-S6.

9.

Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue.

Hartmann E, Fernàndez V, Moreno V, Valls J, Hernández L, Bosch F, Abrisqueta P, Klapper W, Dreyling M, Hoster E, Müller-Hermelink HK, Ott G, Rosenwald A, Campo E.

J Clin Oncol. 2008 Oct 20;26(30):4966-72. doi: 10.1200/JCO.2007.12.0410.

PMID:
18606985
10.

p27(Kip1) immunostaining for the differential diagnosis of small b-cell neoplasms in trephine bone marrow biopsies.

Kremer M, Dirnhofer S, Nickl A, Hoefler H, Quintanilla-Martínez L, Fend F.

Mod Pathol. 2001 Oct;14(10):1022-9.

11.

Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma.

Yatabe Y, Suzuki R, Tobinai K, Matsuno Y, Ichinohasama R, Okamoto M, Yamaguchi M, Tamaru J, Uike N, Hashimoto Y, Morishima Y, Suchi T, Seto M, Nakamura S.

Blood. 2000 Apr 1;95(7):2253-61.

12.

microRNA expression profiles identify subtypes of mantle cell lymphoma with different clinicobiological characteristics.

Navarro A, Clot G, Prieto M, Royo C, Vegliante MC, Amador V, Hartmann E, Salaverria I, Beà S, Martín-Subero JI, Rosenwald A, Ott G, Wiestner A, Wilson WH, Campo E, Hernández L.

Clin Cancer Res. 2013 Jun 15;19(12):3121-9. doi: 10.1158/1078-0432.CCR-12-3077.

13.

Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.

Hoster E, Rosenwald A, Berger F, Bernd HW, Hartmann S, Loddenkemper C, Barth TF, Brousse N, Pileri S, Rymkiewicz G, Kodet R, Stilgenbauer S, Forstpointner R, Thieblemont C, Hallek M, Coiffier B, Vehling-Kaiser U, Bouabdallah R, Kanz L, Pfreundschuh M, Schmidt C, Ribrag V, Hiddemann W, Unterhalt M, Kluin-Nelemans JC, Hermine O, Dreyling MH, Klapper W.

J Clin Oncol. 2016 Apr 20;34(12):1386-94. doi: 10.1200/JCO.2015.63.8387.

PMID:
26926679
14.

Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.

Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, Kubota N, Ishizawa K, Yamamoto J, Watanabe T, Uike N, Choi I, Terui Y, Usuki K, Nagai H, Uoshima N, Tobinai K; Japanese Bendamustine Lymphoma Study Group..

Cancer Sci. 2010 Sep;101(9):2059-64. doi: 10.1111/j.1349-7006.2010.01635.x.

15.

MicroRNAs in mantle cell lymphoma.

Husby S, Geisler C, Grønbæk K.

Leuk Lymphoma. 2013 Sep;54(9):1867-75. doi: 10.3109/10428194.2013.766731. Review.

PMID:
23339447
16.

Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.

Chiarle R, Budel LM, Skolnik J, Frizzera G, Chilosi M, Corato A, Pizzolo G, Magidson J, Montagnoli A, Pagano M, Maes B, De Wolf-Peeters C, Inghirami G.

Blood. 2000 Jan 15;95(2):619-26.

17.

MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma.

Monsálvez V, Montes-Moreno S, Artiga MJ, Rodríguez ME, Sanchez-Espiridion B, Lozano M, Fernández-de-Misa R, Rodríguez-Peralto JL, Piris MA, Ortíz-Romero PL.

Mod Pathol. 2013 Feb;26(2):171-81. doi: 10.1038/modpathol.2012.149. Erratum in: Mod Pathol. 2013 Apr;26(4):617. Espiridión, Beatriz S [corrected to Sanchez-Espiridion, Beatriz].

18.

Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.

Vose JM.

Am J Hematol. 2012 Jun;87(6):604-9. doi: 10.1002/ajh.23176. Review.

19.

Immunohistochemical detection of cdc2 is useful in predicting survival in patients with mantle cell lymphoma.

Hui D, Reiman T, Hanson J, Linford R, Wong W, Belch A, Lai R.

Mod Pathol. 2005 Sep;18(9):1223-31.

20.
Items per page

Supplemental Content

Support Center